TMCnet News
WEALTHMAKERS.COM Issues Bearish Research Reports on APFC, ARIA, CLDX, DBLE, ISF, ISG(M2 PressWIRE Via Acquire Media NewsEdge) WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: American Pacific Corp (NASDAQ:APFC), ARIAD Pharmaceuticals Inc (NASDAQ:ARIA), Celldex Therapeutics Inc (NASDAQ:CLDX), Double Eagle Petroleum Co (NASDAQ:DBLE), ING GROEP N.V. 6.375% ING Perpetual Hybrid Capital Securities (NYSE:ISF), ING Groep NV (NYSE:ISG) Click here to download each report: American Pacific Corp (NASDAQ:APFC): http://www.wealthmakers.com/ireport/22541 ARIAD Pharmaceuticals Inc (NASDAQ:ARIA): http://www.wealthmakers.com/ireport/24221 Celldex Therapeutics Inc (NASDAQ:CLDX): http://www.wealthmakers.com/ireport/24215 Double Eagle Petroleum Co (NASDAQ:DBLE): http://www.wealthmakers.com/ireport/24242 ING GROEP N.V. 6.375% ING Perpetual Hybrid Capital Securities (NYSE:ISF): http://www.wealthmakers.com/ireport/24239 ING Groep NV (NYSE:ISG): http://www.wealthmakers.com/ireport/24238 WealthMakers is powered by WOPR (WealthMakers Online Predictive Research), www.wopronline.com , a network of statistical servers with unbridled computing power to analyze exactly what event ( technicals, fundamentals, earnings, seasonality, short squeeze, group rotation, chart patterns, insider buying/selling and multiple other factors) will move each stock, in which direction, to what % degree, in the specific amount of time and with what degree of probability. Based on IBMs work on Deep Blue (now called "Watson"), this powerful database technology matched with hundreds of data feeds and the ability to find patterns, that humans cannot, has the ability to do the work of hundreds or thousands of analysts without getting tired (24 hours per day / 7 days per week). Our unparalleled technology, trading algorithms and proprietary data generate confident predictions, with clear and concise objectives resulting in unique and innovative research reports that move markets and create exponential returns to our clients. Click here to LIKE us on Facebook: http://www.facebook.com/pages/WealthMakers-Ltd/165424826916060 Click here to FOLLOW us on Twitter: http://www.twitter.com/WealthMakersLtd Click here to access WealthMakers technology: http://www.wealthmakers.com/signup.html Users access these powerful research reports though the PowerTrader Matrix. The Matrix automatically scans through 14,000 stocks, 11 strategies and real-time price updates to find only those stocks that have multiple predictions, at the same time, in the same direction, with no conflicting predictions and the fundamental value of the stock is in-line with the direction of the trade. This powerful technology filters out the exact long/short trades that our trading network need to enter at the precise time and price that they should be entered and exited. To learn more click here: http://www.buyins.com/woprbrochure.pdf WealthMakers Power Trader works because the Market Read strategies have a very high success rate. "accuracy", "average return" and "average # of days in trade" are tracked in real-time and documented at www.buyins.com/images/stats.pdf American Pacific Corp (NASDAQ:APFC) - American Pacific Corporation engages in the manufacture and sale of fine chemicals and specialty chemicals in the United States and internationally. Its Fine Chemicals segment manufactures active pharmaceutical ingredients and registered intermediates to the pharmaceutical industry. This segment s pharmaceutical ingredients are used in drugs with indications in three primary areas: anti-viral, oncology, and central nervous system. The company s Specialty Chemicals segment produces and sells ammonium perchlorate, an oxidizing agent for solid propellant rockets, booster motors, and missiles used in national defense, space exploration, and commercial satellite transportation programs; and sodium and potassium perchlorates that are used in a various applications, including munitions, explosives, propellants, perchloric acid, and initiators. This segment also produces and sells sodium azide, a chemical used in pharmaceutical manufacturing; and Halotron, a series of halocarbon-based clean fire extinguishing agents used in fire extinguishing products ranging from portable fire extinguishers to total flooding systems. Its Other Businesses segment designs, manufactures, and markets electrochemical onsite hypochlorite generation systems that are used in the disinfection of drinking water, control of noxious odors, and the treatment of seawater for municipal, industrial, and offshore customers. This segment is also involved in real estate activities. The company was founded in 1955 and is headquartered in Las Vegas, Nevada. ARIAD Pharmaceuticals Inc (NASDAQ:ARIA) - ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. Its product pipeline includes Ponatinib, an investigational pan BCR-ABL inhibitor, which is being studied in Phase I and II clinical trials in patients with hematologic cancers, including chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia; AP26113, an investigational dual inhibitor of anaplastic lymphoma kinase, which is being studied in a Phase I/II clinical trial in patients with advanced solid tumors comprising non-small cell lung cancer; and Ridaforolimus, an investigational mTOR inhibitor, which is being studied in multiple clinical trials in patients with various types of cancers. The company also focuses on a drug discovery program centered on small-molecule therapies that are molecularly targeted to cell-signaling pathways implicated in cancer. ARIAD Pharmaceuticals, Inc. has a collaboration agreement with Merck for the joint global development, manufacture, and commercialization of ridaforolimus for use in cancer; and license agreements with Medinol and ICON to develop and commercialize ridaforolimus-eluting stents and other medical devices to prevent restenosis or reblockage of injured vessels following interventions in which stents are used in conjunction with balloon angioplasty. The company was founded in 1991 and is headquartered in Cambridge, Massachusetts. Celldex Therapeutics Inc (NASDAQ:CLDX) - Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. The company markets Rotarix to treat rotavirus infection. Its lead drug candidate, rindopepimut (CDX-110), is an immunotherapeutic vaccine in Phase III clinical trial to target the tumor-specific molecule, epidermal growth factor receptor variant III, as well as in Phase II clinical trial for the indication of recurrent glioblastoma. The company s other lead drug candidates comprise CDX-011, an antibody-drug conjugate in Phase IIb clinical trial for metastatic breast cancer and melanoma indication; and CDX-1127, a human monoclonal antibody in Phase I clinical trial for the treatment of lymphoma/leukemia and solid tumors. Its additional clinical and preclinical programs consist of CDX-1401, an Antigen Presenting Cells Targeting Technology program in Phase I/II clinical trial to treat multiple solid tumors; and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor in Phase I clinical for treating cancer, autoimmune disease, and transplant. The company s preclinical products include CDX-1135, a molecule for treating renal disease; and CDX-014, a human monoclonal antibody-drug conjugate for the treatment of ovarian and renal cancer. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Alteris Therapeutics, Inc.; Thomas Jefferson University; 3M Company; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. Celldex Therapeutics, Inc. was founded in 1983 and is headquartered in Needham, Massachusetts. Double Eagle Petroleum Co (NASDAQ:DBLE) - Double Eagle Petroleum Co., an independent energy company, engages in the exploration, development, production, and sale of natural gas and crude oil primarily in the Rocky Mountain Basins of the western United States. The company s properties include the Atlantic Rim coal bed natural gas project located in south central Wyoming; the Pinedale Anticline in the Green River Basin of Wyoming; and the Wind River Basin in central Wyoming, as well as engages in drilling activities in the Moxa Arch and other areas in Southwest Wyoming. It also operates 91 producing wells in the state of Wyoming, 4 wells in Texas, and 1 well in Oklahoma; and transports gas through intrastate gas pipeline. As of December 31, 2011, Double Eagle had estimated proved reserves of 133.9 billion cubic feet of natural gas and 381 thousand barrels of oil; owned interests in approximately 1,200 producing wells; and had an acreage position of 405,726 gross acres in natural gas prone basins primarily located in the Rocky Mountains. The company was founded in 1972 and is based in Denver, Colorado. ING GROEP N.V. 6.375% ING Perpetual Hybrid Capital Securities (NYSE:ISF) - ING Groep N.V., a financial services company, provides banking, investment, life insurance, and retirement services for individuals, families, small businesses, corporations, institutions, and governments worldwide. The company provides savings accounts, mortgage loans, consumer loans, credit card services, and investment products, as well as current account services and payments systems; life and non-life insurance products; asset management products and services; mortgage products; and risk management services. It also offers commercial banking products and services, including lending products, such as structured finance; payment and cash management, and treasury services; and specialized and trade finance, derivatives, corporate finance, debt and equity capital markets, leasing, factoring, and supply chain finance. In addition, the company provides individual endowment, and term and whole life insurance products, as well as traditional, unit-linked, and variable annuity life insurance products for individual and group customers; fire, motor, disability, transport, accident, and third party liability insurance products; employee benefits products and pension funds; retirement services, fixed annuities, mutual funds, and broker-dealer services; and disability insurance products and complementary services for employers and self-employed professionals comprising dentists, general practitioners, and lawyers. Further, the company offers investment management services. ING Groep N.V. operates a network of approximately 280 branches in the Netherlands; and 773 branches in Belgium. The company was founded in 1991 and is headquartered in Amsterdam, the Netherlands. ING Groep N.V. is a subsidiary of Stichting ING Aandelen. ING Groep NV (NYSE:ISG) - ING Groep N.V., a financial services company, provides banking, investment, life insurance, and retirement services for individuals, families, small businesses, corporations, institutions, and governments worldwide. The company provides savings accounts, mortgage loans, consumer loans, credit card services, and investment products, as well as current account services and payments systems; life and non-life insurance products; asset management products and services; mortgage products; and risk management services. It also offers commercial banking products and services, including lending products, such as structured finance; payment and cash management, and treasury services; and specialized and trade finance, derivatives, corporate finance, debt and equity capital markets, leasing, factoring, and supply chain finance. In addition, the company provides individual endowment, and term and whole life insurance products, as well as traditional, unit-linked, and variable annuity life insurance products for individual and group customers; fire, motor, disability, transport, accident, and third party liability insurance products; employee benefits products and pension funds; retirement services, fixed annuities, mutual funds, and broker-dealer services; and disability insurance products and complementary services for employers and self-employed professionals comprising dentists, general practitioners, and lawyers. Further, the company offers investment management services. ING Groep N.V. operates a network of approximately 280 branches in the Netherlands; and 773 branches in Belgium. The company was founded in 1991 and is headquartered in Amsterdam, the Netherlands. ING Groep N.V. is a subsidiary of Stichting ING Aandelen. About WEALTHMAKERS Wealthmakers Online Predictive Research (WOPR) is a distributed computing system that has hundreds of data feeds (economic, weather, geopolitical, interest rates, energy, equities, currencies, commodities, etc.) feeding into a relational database that searches for patterns and determines how a trading instrument has behaved both before and after specific events have taken place in the past. Only about 25% of stocks display patterns at any given time and only about 1% of stocks exhibit all the necessary conditions on any given day to make a trade. That means that out of 14,000 stocks, only about 140 trades are high probability trades that our system would generate a research report on and disseminate the information to clients. This process eliminates the noise and only tells you which stocks have multiple strategies lining up at the same time, in the same direction, with no conflicting predictions and the fundamental valuation is in-line with the prediction! Strategies include: EARNINGS - Most stock price histories show random or unpredictable movements around earnings reports. But some repeat the same pattern quarter after quarter, year after year. Earnings predict probability, price move and length of move before and after all US stock earnings reports. FRICTION FACTOR - Friction Factor is based on the relationship between the price of a stock and the volume at which it's bought and sold. Normal and abnormal Friction factor patterns can help you time your buying and selling decisions for maximum earnings potential. GATS - The Global Automated Trading System (GATS) combines neural networks and genetic algorithms to reduce investment risks. GATS selects the highest probability trades in stocks, bonds, options, commodities, currencies and private equities, delivering precise, predictive and profitable data. GROUP SECTOR - Certain institutions can exert buying or selling pressure over an entire industry group, pushing prices higher. Group Sector identifies stocks that most closely match their group's movement and generate powerful group consensus trading signals to help you profit from the herd mentality. PATTERN SCANNER - describes the current technical situation in your stock. It displays the technicals, trend conditions and seasonal factors and automatically discovers how that stock has performed in the trading days following the occurrences of the event or combination of events. This technology automatically scans using complex historical queries based on what event is taking place right now in the stock. It then displays the probability, expected return and number of trading days for the expected move. EVENTS - This technology automatically tracks "Trigger Events" that positively or negatively affect the value of a stock or its perceived value among analysts ranging from price fluctuations to natural disasters and political shifts. The results reveal patterns that can predict market movements. RegSHO NAKED SHORTS - SEC Regulation SHO mandates that if a clearing agent holds a fail-to-deliver position for 13 consecutive settlement days, it must purchase securities to close out its position, a.k.a. a forced cover. WealthMakers aggregates data from NYSE, AMEX, NASDAQ, OTCBB and PINKSHEETS to track stocks that are about to have forced covers. SEASONALITY - Seasonality analyzes more than 20 years of data to determine if stocks have a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. SQUEEZETRIGGER - Our proprietary database of more than 3,500,000,000 short sale transactions allows us to calculate the exact price at which the total short interest is short in each stock. Squeeze Trigger Alerts let you know exactly when a short squeeze will start and how to trade profitably. VALUATION - A stock's value is a function of its forecasted earnings per share and forecasted earnings growth, as well as profitability, interest and inflation rates. Valuation use these metrics to determine at what price a stock is undervalued or overvalued, so that you can make investment decisions accordingly. INSIDER - Significant stock sales or purchases by company "insiders" (officers or directors) can be a predictor of future price movements, up or down. The Insider strategy tracks these actions and correlates them with historical data to give you an investment edge. DISCLAIMER: WEALTHMAKERS is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. WEALTHMAKERS has not been compensated by any of the above mentioned companies specifically for this report. Past performance is not indicative of future results. Please visit our web site, www.wealthmakers.com , for complete risks and disclosures. Contact: WEALTHMAKERS 1-516-858-1113 [email protected] www.wealthmakers.com CONTACT: WealthMakers Tom Ronk [email protected] http://www.WealthMakers.com ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.com on the world wide web. Inquiries to [email protected])). (c) 2013 M2 COMMUNICATIONS |